Europe's highest court upheld a $63 million fine against pharmaceutical giant AstraZeneca for blocking the generic version of its Losec ulcer medication in the EU marketplace.

The European Commission originally fined AstraZeneca $72 million in 2005, after finding that the company had deliberately lied to member state patent offices in an effort to extend its protection of Losec.